Remote Hearing Tests for Head and Neck Cancer Patients
This study is looking at different ways to monitor hearing in people with head and neck squamous cell carcinoma (HNSCC) who are receiving cisplatin chemotherapy and/or radiation. These treatments can sometimes cause hearing loss. The study wants to see if offering hearing tests (audiometry) closer to your home or that you can do yourself remotely, helps more people get their hearing checked. The main goal is to see how many patients complete at least one hearing test up to 12 months after their treatment. You might be able to join if you are an adult (18 or older) with pathologically proven HNSCC. The study aims to enroll 118 participants.
- Study design
- This interventional study plans to enroll 118 participants. It compares standard in-person hearing tests with options for closer-to-home or self-administered remote hearing tests.
- What's involved
- You would undergo hearing tests at the start of the study and again at 3 and 12 months after your chemotherapy and/or radiation treatment. Some participants may also complete an interview.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your participation in hearing monitoring will be tracked for up to 12 months after your treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Nicole C Schmitt, MD, FACS · PRINCIPAL_INVESTIGATOR · Emory University Hospital/Winship Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Proportion of patients who complete at least one post-treatment audiogramUp to 12 months post-treatment
The incidence of follow-up audiometry relative to the targeted intervention will be assessed using a Z test for the equality of two proportions. An ordinal logistic regression analysis with mixed effects and calculations of odds ratios and 95% confidence intervals will be applied to identify associations between follow-up audiometry and intervention after adjustment for covariates including age, sex, race/ethnicity, pre-existing hearing loss, comorbidities, smoking, cisplatin dose (individual and cumulative) and cochlear radiation dose will be performed to assess whether the targeted intervention for at-risk patients is an independent predictor of increased overall participation.